Ipsen S.A. publie son Rapport financier semestriel 2023

Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline®, growing by 27.5% at CERStrong pipeline...

Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS,...